Strategies for Managing Patients with Venous Thromboembolism
Cardiology
Curriculum:
Managing patients with VTE
Managing patients with VTE
Credits:
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
August 19, 2014
August 19, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
cardiologists, pharmacists, ER physicians, hospitalists, hematologists, NPs/PAs, and other clinicians managing patients with ACS
Relevant Terms:
Myocardial Infarction, Thrombosis, Anticoagulant Therapy
David Garcia, MD
David Garcia, MD
Professor of Medicine
Division of Hematology
University of Washington School of Medicine
Seattle, WA
Bio
Dr. David Garcia completed his undergraduate studies at Duke University and received his medical degree from the University of Alabama. Dr. Garcia completed internal medicine residency at The Johns Hopkins Hospital and a hematology fellowship at the University of Washington, where he became a Professor of Medicine in 2013.
Dr. Garcia has been either an investigator or steering committee member for numerous clinical trials related to the prevention and treatment of thromboembolic disease, and he is the immediate past-President of the Anticoagulation Forum, a U.S. national interest group of anticoagulation care providers. Dr. Garcia's primary research interests include cancer-associated thrombosis, the treatment of warfarin-associated coagulopathy and peri-procedural anticoagulation. He has authored or co-authored peer-reviewed publications in journals such as Blood, Archives of Internal Medicine, New England Journal of Medicine, the British Journal of Hematology, Stroke and Circulation. Dr. Garcia was very involved with the development of the most recent American College of Chest Physicians Guidelines on Anti-thrombotic Therapy and is Special Editor for Evidence-based Focused Reviews at Blood.
Stephan Moll, MD
Stephan Moll, MD
Professor of Medicine
Department of Medicine, Division of Hematology-Oncology
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Bio
Dr. Moll received his medical degree from Freiburg University, Germany, and did a pathology residency at the Institute of Pathology, University of Aachen, Germany. He completed an internship/residency in internal medicine and a hematology-oncology fellowship at Duke University Medical Center, North Carolina, and a 1-year clinical coagulation fellowship at the University of North Carolina (UNC), Chapel Hill. Dr. Moll has been a faculty member at the University of North Carolina in the Department of Medicine and the Division of Hematology-Oncology for the last 12 years.
His clinical focus is classical hematology-coagulation, particularly thrombosis and thrombophilia. Dr. Moll’s research interests include clinical trials on new anticoagulants, better use of established anticoagulants, antiphospholipid antibody syndrome and postthrombotic syndrome. He takes a focused interest in clinical-medical education. He is a co-founder of the national patient advocacy group NBCA (National Blood Clot Alliance; www.stoptheclot.org), a board member of the national non-profit anticoagulation provider organizations AC-Forum (Anticoagulation Forum; www.acforum.org) and Hemophilia and Thrombosis Research society (www.htrs.org), and recently started the University of North Carolina Blood Clot Outreach Program (www.clotcotconnect.org).
| 1. | Identify patients at-risk for VTE and determine whether those patients need pharmacologic prophylaxis against VTE or are being undertreated | 2. | List the risks and benefits of anticoagulation therapy, with an emphasis on tradeoffs unique to secondary VTE prevention |
| 3. | Discuss data related to new oral anticoagulants which might be relevant to the treatment and secondary prevention of VTE | 4. | Compare current anticoagulant therapies to new oral agents with regards to cost, convenience, safety, efficacy, and pharmacology |
| 5. | Develop strategies to improve the accuracy and facility of communication with patients and caregivers regarding the prevention of VTE and the benefits and risks of both inpatient and outpatient anticoagulation therapy |
| 1. | Identify patients at-risk for VTE and determine whether those patients need pharmacologic prophylaxis against VTE or are being undertreated |
| 2. | List the risks and benefits of anticoagulation therapy, with an emphasis on tradeoffs unique to secondary VTE prevention |
| 3. | Discuss data related to new oral anticoagulants which might be relevant to the treatment and secondary prevention of VTE |
| 4. | Compare current anticoagulant therapies to new oral agents with regards to cost, convenience, safety, efficacy, and pharmacology |
| 5. | Develop strategies to improve the accuracy and facility of communication with patients and caregivers regarding the prevention of VTE and the benefits and risks of both inpatient and outpatient anticoagulation therapy |
Disclosure Policy Statement
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME/CNE) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.
Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
Faculty Disclosures
David Garcia, MD is a consultant for Bristol-Myer Squibb and PFizer, Daiichi Sankyo, CSL Behring, Boehringer-Ingelheim and Bayer.
Stephan Moll, MD is a consultant for Janseen Pharmaceuticals Inc. and Daiichi Sankyo.
Off-Label Discussions
The faculty members do plan on discussing unlabeled/investigational uses of a commercial product. Faculty will discuss the off-label use of apixaban and edoxaban for venous thromboembolism treatment.
Accreditation Planning
Michael Burk, Boston University School of Medicine planner, has no relevant financial relationships with any commercial interest.
Patti-Ann Collins, DNP, MSN/MBA, RN, Boston University’s School of Medicine’s Lead Nurse Planner, has no relevant financial relationships with any commercial interest.
Christina Cove, MD Boston University’s Continuing Medical Education department’s independent CME content reviewer, has nothing to disclose with regards to commercial support.
Ms. Elizabeth Goldstein, Executive Director of Anticoagulation Forum, has nothing to disclose with regards to commercial support.
Elaine Hylek, MD Boston University’s School of Medicine CME Course Director, is a consultant for Bayer, Bristol Myers Squibb and Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Johnson and Johnson. She also receives grant/research from Bristol Myers Squibb/Pfizer and Johnson and Johnson. She additionally has spoken at symposiums for Bayer, Boehringer Ingelheim and Bristol Myers Squibb/Pfizer.
Terri Schnurr, RN Anticoagulation Forum’s Nursing Course Advisor, has nothing to disclose with regards to commercial support.
Julie White, MS, Boston University School of Medicine planner, has no relevant financial relationships with any commercial interest.
Credit Designations/Accreditation Statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Anticoagulation Forum. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and co-provided by Anticoagulation Forum. Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
CNE Contact Hours: 1.0, all of which is pharmacology credit worthy.
Nurses will receive contact hours after completion of an evaluation and claim for credit form.
Continuing Pharmacy Education Credits
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendance and completion of program evaluations at the conclusion of the program are required for a statement of credit. This knowledge-based activity is approved for 1.0 Contact Hours (0.1 CEUs). UAN: 0060-9999-14-059-H01-P. Expiration date: August 19, 2015.
How to Receive credit:
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.0 CNE contact hours, all of which are pharmacology credit worthy, and pharmacists will receive 1.0 Contact Hours (0.1 CEUs). Statement of credit will be available to print from your user history page.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.0 CNE contact hours, all of which are pharmacology credit worthy, and pharmacists will receive 1.0 Contact Hours (0.1 CEUs). Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians, nurses and pharmacists who successfully complete the post-test and evaluation will resepectively receive CME, CNE or ACPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
*Note to Pharmacists: to receive CE credits you must submit your NABP ID number. You will be prompted to submit your ID number at the end of the activity, after completing the posttest, when claiming your credits. This is mandatory and the CE credits are not valid unless an NABP ID is submitted.
If you do not have an ID number you can obtain one at the following link:
http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/
Program Code: E.VTEAF14
For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
To view Boston University's Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
RealCME Privacy Policy: http://www.realcme.com/cms/privacypolicy
Commercial Support
This activity is supported by an educational grants from Bristol Myer Squibb and Pfizer Inc., Daiichi Sankyo Inc., and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
